GleamWall
中文EN

IMUX IMMUNIC, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1280776 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY135.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-223.2%
ROA-144.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.4%
Debt / equity0.00x
Current ratio4.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-36.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$23.95M$25.93M$25.63M$19.07M$20.01M$21.37M$21.53M$21.62M
SG&A expense$19.42M$9.40M$7.61M$4.26M$5.98M$5.71M$5.29M$4.01M
Operating income-$43.37M-$35.33M-$33.23M-$23.33M-$25.99M-$27.08M-$26.82M-$25.63M
Net income-$42.31M-$34.10M-$32.59M-$19.30M-$25.58M-$26.82M-$25.47M-$25.18M
EBITDA-$43.33M-$35.29M-$33.20M-$23.29M-$25.95M-$27.04M-$26.78M-$25.60M
EPS (basic)-0.99-0.80-1.08—-1.32-2.03-2.51—
EPS (diluted)-0.99-0.80-1.08—-1.32-2.03-2.51—
Dividends declared per share0.000.000.000.000.000.000.000.00
Weighted avg. shares (diluted)42.80M42.51M30.14M—19.39M13.22M10.13M—
Banking
Provision for credit losses$56,000$209,000$151,000$341,000$48,000$55,000$53,000-$121,000
Balance sheet
Cash & equivalents$131.96M$155.10M$186.63M$15.48M$35.13M$55.31M$14.30M$35.67M
Current assets$135.09M$157.83M$188.76M$22.87M$39.27M$59.84M$18.98M$39.33M
PP&E, net$832,000$771,000$566,000$608,000$640,000$612,000$572,000$545,000
Total assets$136.42M$159.17M$189.74M$24.05M$40.70M$61.43M$20.52M$40.87M
Current liabilities$31.55M$31.26M$38.36M$30.62M$30.08M$27.31M$25.59M$22.18M
Total liabilities$31.95M$31.59M$38.51M$30.73M$30.20M$27.52M$25.80M$22.44M
Shareholders' equity$104.47M$127.58M$151.23M-$6.67M$10.50M$33.91M-$5.29M$18.43M
Shares outstanding12.04M13.64M13.62M15.88M98.65M98.65M90.15M90.15M
Cash flow statement
Operating cash flow-$28.39M-$31.00M-$17.30M-$19.28M-$20.14M-$24.61M-$21.78M-$22.96M
Capital expenditure$104,000$249,000$2,000$11,000$67,000$36,000$47,000$3,000
Free cash flow-$28.49M-$31.25M-$17.30M-$19.29M-$20.21M-$24.64M-$21.82M-$22.97M
Investing cash flow-$104,000-$249,000-$2,000-$11,000-$67,000-$36,000-$47,000-$3,000
Financing cash flow$5.32M$118,000$188.64M$59,000$0$65.52M$0$77,000
Depreciation & amortization$38,000$34,000$33,000$42,000$40,000$43,000$43,000$35,000
Stock-based compensation$13.91B$6.78B$4.47M$1.31M$3.61B$1.90B$2.04M$1.99M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.